XML 87 R76.htm IDEA: XBRL DOCUMENT v3.26.1
Long-term Debt - Additional Information (Details) - USD ($)
3 Months Ended 6 Months Ended
Feb. 12, 2026
Jun. 30, 2026
Jun. 30, 2026
Nov. 18, 2025
Debt Instrument [Line Items]        
Unamortized deferred financing costs   $ 3,900,000 $ 3,900,000  
Unamortized original issue discount costs   11,400,000 11,400,000  
Amortization expense related to deferred financing costs and original issue discount.   800,000 1,200,000  
Credit Agreement | JPMorgan Chase Bank, N.A. | Avadel Pharmaceuticals Plc        
Debt Instrument [Line Items]        
Aggregate principal amount $ 1,525,000,000      
Credit Agreement | JPMorgan Chase Bank, N.A. | Senior Secured Term Loan A Facility | Avadel Pharmaceuticals Plc        
Debt Instrument [Line Items]        
Aggregate principal amount $ 750,000,000      
Line of credit facility maturity date Feb. 12, 2031      
Credit Agreement | JPMorgan Chase Bank, N.A. | Senior Secured Term Loan B Facility | Avadel Pharmaceuticals Plc        
Debt Instrument [Line Items]        
Aggregate principal amount $ 775,000,000      
Line of credit facility maturity date Aug. 12, 2031      
Credit Agreement | SOFR | JPMorgan Chase Bank, N.A. | Senior Secured Term Loan A Facility | Avadel Pharmaceuticals Plc        
Debt Instrument [Line Items]        
Interest rate added to base rate (as a percent) 2.75%      
Credit Agreement | SOFR | JPMorgan Chase Bank, N.A. | Senior Secured Term Loan B Facility | Avadel Pharmaceuticals Plc        
Debt Instrument [Line Items]        
Interest rate added to base rate (as a percent) 2.75%      
Credit Agreement | Alternate Base Rate | JPMorgan Chase Bank, N.A. | Senior Secured Term Loan A Facility | Avadel Pharmaceuticals Plc        
Debt Instrument [Line Items]        
Interest rate added to base rate (as a percent) 1.75%      
Credit Agreement | Alternate Base Rate | JPMorgan Chase Bank, N.A. | Senior Secured Term Loan B Facility | Avadel Pharmaceuticals Plc        
Debt Instrument [Line Items]        
Interest rate added to base rate (as a percent) 1.75%      
Bridge Term Loan Credit Agreement | JPMorgan Chase Bank, N.A. | Avadel Pharmaceuticals Plc        
Debt Instrument [Line Items]        
Aggregate principal amount       $ 1,500,000,000
Financing costs   $ 7,400,000 $ 7,400,000